搜尋
MDxHealth SA
MDXH添加自選
0.507USD
+0.096+23.48%
收盤 07/01, 16:00（美東）報價延遲15分鐘
26.04M總市值
虧損本益比TTM
關鍵數據
0.420今開
0.540最高
2.22M成交量
虧損本益比TTM
虧損本益比動
--股利TTM
4.31%換手率
0.411昨收
0.414最低
820.47K成交額
虧損本益比靜
-1.29市淨率
0.00%股息率 TTM
-19.77%ROA
5.33052週最高
2.06量比
-38.07M淨利潤
51.36M總股本
-0.6509每股盈餘TTM
0.56Beta
-2440.41%ROE
0.68052週最低
30.71%振幅
56.05%毛利率
26.04M總市值
-8.98回報/風險
4.00%風險率
TradingKey MDxHealth SA股票評分
單位: USD 更新時間: 2026-06-30操作建議
MDxHealth SA當前公司基本面數據相對健康，增長潛力很大。當前估值低估，在生物技術與醫療研究行業排名130/387位。機構持股佔比非常高，近一月多位分析師給出公司評級為買入。最高目標價為2.90。中期看，股價處於下降通道。近一個月，市場表現非常差，但基本面評分較高。目前股價在壓力位和支撐位之間，可以做區間波段操作。
MDxHealth SA評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
公司輿情
過去24小時
熱度
過冷
過熱
看好
MDxHealth SA亮點
亮點風險
MDxHealth SA is a Belgium-based healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The Company's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.
業績高增長
公司營業收入穩步增長，連續3年增長53.68%
估值高估
公司最新PE估值-0.63，處於3年歷史高位
機構減倉
最新機構持股25.38M股，環比減少1.08%
史蒂文·科恩持倉
明星投資者史蒂文·科恩持倉，最新持倉63.68K股
活躍度增加
近期活躍度增加，過去20天平均換手率3.02
分析師目標
基於
6
分析師
強力買入
評級
6.040
目標均價
+325.35%
漲幅空間
MDxHealth SA新聞
即將為您帶來更多新聞，敬請期待。 。 。
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
MDxHealth SA簡介
MDxHealth SA is a Belgium-based healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The Company's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.
公司代碼MDXH
公司MDxHealth SA
CEOMr. Michael K. McGarrity
網址https://mdxhealth.com/
相關品種
-0.64%
-0.05%
-2.95%
-0.23%
-2.41%
-1.64%
-0.22%
+1.75%
-0.29%
-0.79%
+0.26%
-2.00%
-2.10%
-2.41%
+1.68%
0.00%
+0.19%
-1.97%
+0.06%
-0.44%熱門品種
52271.000
+16.700 (+0.03%)
29792.400
-6.900 (-0.02%)
7478.800
+3.300 (+0.04%)
15346.000
-9.000 (-0.06%)
69519.000
+34.000 (+0.05%)
6277.100
+1.700 (+0.03%)
67.924
-0.044 (-0.07%)
294.380
+5.020 (+1.73%)
197.580
-2.510 (-1.25%)
4037.450
+6.680 (+0.17%)
常見問題
MDxHealth SA(MDXH)的當前股價是多少？
MDxHealth SA(MDXH)的當前股價是 0.41。
MDxHealth SA 的股票代碼是什麼？
MDxHealth SA的股票代碼是MDXH。
MDxHealth SA股票的52週最高點是多少？
MDxHealth SA股票的52週最高點是5.33。
MDxHealth SA股票的52週最低點是多少？
MDxHealth SA股票的52週最低點是0.68。
MDxHealth SA的市值是多少？
MDxHealth SA的市值是21.09M。
現在MDxHealth SA(MDXH)的股票是買入、持有還是賣出？
根據分析師評級，MDxHealth SA(MDXH)的總體評級為買入，目標價格為2.90。
MDxHealth SA(MDXH)股票的每股收益（EPS TTM）是多少
MDxHealth SA(MDXH)股票的每股收益（EPS TTM）是-0.67。